Erratum
for
Bubley et al., J Clin Oncol 17 (11) 3461-3467.
Journal of Clinical Oncology, Vol 25, No 9 (March 20), 2007: pp. 1154
© 2007 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2007.11.1963
ERRATUM
The November 1999 article by Bubley et al entitled, "Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group" (J Clin Oncol 17:3461-3467, 1999) contained an error.
In the "Recommendations for Eligibility Criteria" section, the first sentence under "Testosterone levels/suppression" was given as:
"To standardize this population as much as possible, all patients without surgical castration should have a serum testosterone level less than 50 ng/mL."
While it should have read:
"To standardize this population as much as possible, all patients without surgical castration should have a serum testosterone level less than 50 ng/dL."
The online version has been corrected in departure from the print.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
|
